Verorab Rabies Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Sciences Techniques and Technologies of Bamako

Conditions

MalariaMalaria,Falciparum

Phase 1

Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

CompletedNCT05135273

National Institute of Allergy and Infectious Diseases (NIAID)Malaria,Falciparum

Start: 2021-10-22End: 2023-06-21Updated: 2024-05-06

Phase 2

Controlled Human Malaria Infection evaluation of Plasmodium falciparum malaria vaccine ProC6C-AlOH/Matrix-Mtm in healthy Malian adults

Active, not recruitingPACTR202404598604620

University of Sciences Techniques and Technologies of BamakoMalaria

Start: 2024-03-01Target: 34Updated: 2026-09-14

Related Papers

Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study.

2025-12-16

Magnitude and durability of ProC6C-AlOH/Matrix-M <sup>tm</sup> vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial

Human Vaccines & Immunotherapeutics2025-04-104 citations

ProC6C, a novel multi-stage malaria vaccine, elicits functional antibodies against the minor and central repeats of the Circumsporozoite Protein in human adults

Frontiers in Immunology2024-11-019 citations